“Comment on ‘Apixaban vs. aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischemic attack: subgroup analysis of the ARTESiA randomized controlled trial’” (2025) Bleeding, Thrombosis and Vascular Biology, 4(2). doi:10.4081/btvb.2025.179.